Alnylam Pharmaceuticals
ALNY
$451.67
Share price
11.75%
Change (1 day)
102.52%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - Total assets
Total assets on the balance sheet as of December 2024 : A$6.75 Billion
According to Alnylam Pharmaceuticals 's latest financial reports the company's total assets are A$6.75 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Alnylam Pharmaceuticals - Total assets on balance sheet (from 2003 to 2024)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2024-12-31 | A$6.81 B | 21.26% |
| 2023-12-31 | A$5.62 B | 7.87% |
| 2022-12-31 | A$5.21 B | 3.7% |
| 2021-12-31 | A$5.02 B | 13.42% |
| 2020-12-31 | A$4.43 B | 29.52% |
| 2019-12-31 | A$3.42 B | 53.03% |
| 2018-12-31 | A$2.23 B | -12.51% |
| 2017-12-31 | A$2.55 B | 45.84% |
| 2016-12-31 | A$1.75 B | -7.95% |
| 2015-12-31 | A$1.90 B | 44.28% |
| 2014-12-31 | A$1.31 B | 179.8% |
| 2013-12-31 | A$0.47 B | 70.4% |
| 2012-12-31 | A$0.27 B | 0.63% |
| 2011-12-31 | A$0.27 B | -28.98% |
| 2010-12-31 | A$0.38 B | -27.75% |
| 2009-12-31 | A$0.53 B | -31.84% |
| 2008-12-31 | A$0.78 B | 39.2% |
| 2007-12-31 | A$0.56 B | 85.51% |
| 2006-12-31 | A$0.30 B | 126.52% |
| 2005-12-31 | A$0.13 B | 57.34% |
| 2004-12-31 | A$85.42 M | 80.48% |
| 2003-12-31 | A$47.33 M | 65.52% |
| 2002-12-31 | A$28.59 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 | A$1.61 B | -76.09% | 🇺🇸 USA |
 | A$60.19 B | 790.56% | 🇺🇸 USA |
 | A$6.31 B | -6.53% | 🇺🇸 USA |
 | A$3.50 B | -48.11% | 🇺🇸 USA |
 | A$0.14 B | -97.79% | 🇺🇸 USA |
 | A$162.99 B | 2,311.47% | 🇨🇭 Switzerland |
 | A$220.29 B | 3,159.26% | 🇫🇷 France |
 | A$62.68 B | 827.50% | 🇮🇱 Israel |